Hematology Diagnostics Market

The global Hematology Diagnostics Market is valued at USD 5.7 Billion in 2023 and is projected to reach a value of USD 8.1 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 3.9% between 2024 and 2032. The Market is driven by increasing prevalence of blood disorders and the growing demand for automated hematology analyzers to improve diagnostic efficiency.

Key Highlights

• In 2023, North America dominated the market with a 44.5% market share
• By product type, the hematology consumables dominated the market in 2023
• Based on test type, the complete blood count (CBC) segment dominated the market in 2023
• By End Use, the diagnostics labs dominated the market share in 2023
• The rising adoption of point-of-care testing (POCT) and the integration of AI and machine learning for enhanced diagnostic accuracy are driving the market growth of the Hematology Diagnostics market

Product Type Overview

Based on product type, the Hematology Diagnostics market is segmented into hematology instruments and hematology consumables. The hematology consumables segment dominated the market in 2023.

Hematology consumables play an important role in the day-to-day operations of diagnostic labs and healthcare facilities. They are used for all hematology tests and procedures. Hence, hematology diagnostic consumables are in constant demand due to the need for continuous testing and care for patients. Additionally, the growth of the hematology consumables segment is also driven by the continuous development of medical technologies that often need specialized consumables to operate. For instance, in August 2023, FDA clearance enables laboratories to run complete blood counts (CBCs) as part of Abbott’s Alinity family of diagnostic products.

Test Type Overview

The test type segment is divided into complete blood count, platelet function, hemoglobin, and hematocrit. The complete blood count (CBC) segment dominated the market in 2023 with a significant market share.

CBC is one of the most widely used and important blood tests in healthcare, as it provides detailed information about a patient’s blood composition, including red blood cells, white blood cells, platelets, and hemoglobin. The continued need for CBC testing is used in many different fields of medicine, from regular medical check-ups to diagnosing and monitoring blood disorders. For instance, in August 2023, Abbott received U.S. Food and Drug Administration clearance for its advanced Alinity® h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott’s Alinity family of diagnostic products.

Regional Overview

In 2023, the North America captured 44.5% of the revenue share.

The North America Hematology Diagnostics market is experiencing rapid growth, driven by the increasing prevalence of hematological disorders, technological advancements, and rising healthcare expenditure. It focuses on trends like automated analyzers and AI integration, detailing key players and their impact on the Hematology Diagnostics market. For instance, in March 2023, Danaher Corporation, a global science and technology innovator, announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation. The multi-year partnership aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next-generation engineered cell products.

The U.S. Hematology Diagnostics market is driven by the increasing incidence of hematologic malignancies and disorders, alongside advancements in diagnostic technologies like high-throughput hematology analyzers. For instance, in August 2023, Abbotts Alinity H-Series hematology system has received 510(k) approval from the U.S. Food and Drug Administration. The system is capable of processing up to 119 full blood count tests per hour and can seamlessly integrate with existing core laboratory workflows. It also features hands-free automatic maintenance and offers customizable reports and rules for streamlined system management.

In Asia Pacific, the Hematology Diagnostics market is experiencing significant growth due to the rising prevalence of blood disorders and increasing healthcare expenditure. Furthermore, advancements in diagnostic technologies, such as automated hematology analyzers and point-of-care testing, are driving market expansion. Additionally, the regions growing awareness of early disease detection and improving healthcare infrastructure further boost the demand for hematology diagnostics.

The China Hematology Diagnostics market is experiencing significant growth due to the rising prevalence of hematological diseases and an increasing emphasis on early diagnosis. There is a growing demand for advanced diagnostic technologies, such as automated hematology analyzers and molecular diagnostic tools. Additionally, the Chinese government is initiating efforts to improve healthcare access and infrastructure, along with growing investments in research and development, which are further propelling market growth in the country.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Point-of-Care Testing: Point-of-care testing (POCT) refers to medical diagnostic testing performed at or near the site of patient care, providing immediate results that can guide treatment decisions
• Growing Awareness and Screening Initiatives: Public health campaigns and educational programs have significantly increased understanding of conditions such as anemia, leukemia, and other blood-related diseases, encouraging individuals to seek regular screenings and check-ups
• Focus on Chronic Disease Management: Chronic conditions such as anemia, sickle cell disease, and various leukemias require ongoing monitoring and regular diagnostic testing to manage symptoms effectively and prevent complications

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Rising prevalence of blood disorders

The Hematology Diagnostics market trends include the rising prevalence of blood disorders, driven by aging populations, genetic predisposition, and lifestyle changes. The increased emphasis on preventive health care and early detection of disease drives the need for routine health checks and hematology tests. In addition, the growing healthcare infrastructure makes it easier for more people to access comprehensive blood testing in both diagnostic labs and healthcare settings. Additionally, recent technological advancements in the field of cell counters and hematology analyzers, coupled with the increased automation of critical analysis steps, have brought about significant changes that have greatly improved laboratory work.

High cost of advanced diagnostics

The high cost of advanced diagnostics in the hematology market stems from the sophisticated technologies involved in developing and manufacturing diagnostic equipment. Automated hematology analyzers, flow cytometers, and molecular diagnostics tools are designed to provide highly accurate and detailed information, which requires the integration of complex hardware and software. These devices often incorporate innovations such as AI algorithms, machine learning, and high-throughput processing, which raise the overall production cost.

Competitive Landscape

The Hematology Diagnostics market is characterized by a dynamic and evolving environment with several key players and their ongoing advancements. Major players are Abbott, Sysmex Corporation, F. Hoffman-La Roche Ltd., Beckman Coulter Ltd., Bio-Rad Laboratories Ltd., Siemens Healthineers AG, Horiba Ltd, HemoCue AB, Danaher Corporation, and other companies. These companies invest heavily in R&D to introduce cutting-edge hematology analyzers, improving automation, accuracy, and speed. Many players are entering into strategic partnerships and collaborations with hospitals, diagnostic labs, and research institutes to broaden their market reach and enhance product development.

The key players in the global Hematology Diagnostics market include - Abbott among others.

Recent Market Developments

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

• In July 2024, Biogen Inc., Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD). The development of tau-specific blood-based biomarkers that can measure a patient’s tau burden could provide critical insights into the underlying pathological processes of AD and may help advance the development of a new generation of therapies impacting tau pathology

Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

• In May 2024, Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV® assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key®, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter’s family of Access Immunoassay Analyzers

The global Hematology Diagnostics market can be categorized as Product Type, Test Type, End-Use and Region.